UK Approves Monthly Maintenance Dosing for Alzheimer’s Drug Leqembi
Eisai and Biogen announced that the UK Medicines and Healthcare products Regulatory Agency has approved a once-every-four-weeks IV maintenance dosing regimen for Leqembi (lecanemab), an…
Read More...
Read More...
